Lycia Therapeutics, a clinical-stage biotechnology company, has successfully closed an oversubscribed $75 million Series D financing round. The funding is earmarked to advance its innovative pipeline of protein degraders for autoimmune and allergic diseases. Alongside the financing, the company has also bolstered its leadership team with key executive appointments to guide its next growth phase.
Strategic Financing to Propel Clinical Trials
The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also saw participation from new backers Adage Capital Management, HBM Healthcare Investments, and OrbiMed. Continued support from established investors like Eli Lilly and Company and Venrock Healthcare Capital Partners underscores strong confidence in the company's platform.
Proceeds will directly support the clinical development of Lycia’s lead programs, LCA-0061 for food allergies and LCA-0321 for Graves’ disease. The company aims to advance these candidates to achieve early clinical proof-of-concept in patients. This capital infusion will also enable the progression of its broader pipeline of cataLYTAC™ degraders toward clinical trials.
Pioneering Protein Degradation Technology
Lycia is pioneering the development of therapeutics using its proprietary LYTAC (Lysosomal Targeting Chimera) platform. This technology is designed to create degraders that catalytically eliminate disease-causing extracellular proteins. The company's initial focus is on addressing significant unmet needs in autoimmune, inflammatory, and allergic diseases.
Vish Sridharan of Janus Henderson Investors expressed confidence in Lycia's approach to selectively depleting harmful proteins. He noted that the company's degraders could represent a best-in-class option for patients with immune-mediated conditions. This perspective highlights the transformative potential of Lycia's technology in patient care.
Strengthening the Executive Team
To support its clinical and financial strategy, Lycia has appointed Amy Bachrodt as its new Chief Financial Officer. Ms. Bachrodt brings over 18 years of finance leadership from companies like Maze Therapeutics and Genentech. Her expertise in capital markets and strategic finance will be crucial as the company advances its programs.
The company also announced the promotion of Karen Flick to General Counsel from her previous role as Senior Vice President, Legal. With nearly 25 years of legal expertise in the biotechnology sector, she is well-equipped to guide Lycia's growth. Her experience spans intellectual property, corporate law, and governance for both private and public companies.
Future Outlook and Company Vision
Aetna Wun Trombley, President and CEO of Lycia, stated that the company is now well-positioned to execute its clinical plans. She emphasized the near-term goal of demonstrating Phase 1 clinical proof-of-concept in patients. The ultimate vision is to redefine treatment for individuals living with chronic immune-mediated diseases.
With a substantial $75 million in new funding and a reinforced executive team, Lycia Therapeutics is poised for a pivotal stage of clinical development. The company's focus on its novel LYTAC platform to degrade disease-causing proteins holds significant promise for patients with challenging autoimmune and allergic conditions. This strategic advancement marks a key milestone in its mission to transform treatment paradigms in immunology.